Adalimumab (anti-TNF-alpha) Therapy to Improve the Clinical Course of Adult-onset Still's Disease: the First Case Report
Overview
Authors
Affiliations
Adult-onset Still's disease: A disease at the crossroad of innate immunity and autoimmunity.
Rao S, Tsang L, Zhao M, Shi W, Lu Q Front Med (Lausanne). 2022; 9:881431.
PMID: 36072947 PMC: 9442343. DOI: 10.3389/fmed.2022.881431.
Progress in Biological Therapies for Adult-Onset Still's Disease.
Galozzi P, Bindoli S, Doria A, Sfriso P Biologics. 2022; 16:21-34.
PMID: 35481241 PMC: 9038152. DOI: 10.2147/BTT.S290329.
Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.
Sfriso P, Bindoli S, Galozzi P Drugs. 2018; 78(12):1187-1195.
PMID: 30069732 DOI: 10.1007/s40265-018-0956-9.
Adult Onset Still's Disease: A Review on Diagnostic Workup and Treatment Options.
Gopalarathinam R, Orlowsky E, Kesavalu R, Yelaminchili S Case Rep Rheumatol. 2016; 2016:6502373.
PMID: 27042373 PMC: 4794578. DOI: 10.1155/2016/6502373.
Treatment of adult-onset Still's disease: a review.
Jamilloux Y, Gerfaud-Valentin M, Henry T, Seve P Ther Clin Risk Manag. 2015; 11:33-43.
PMID: 25653531 PMC: 4278737. DOI: 10.2147/TCRM.S64951.